Last reviewed · How we verify
Low dose WenXin keli
WenXin keli is a traditional Chinese medicine formulation that modulates cardiac electrophysiology and reduces arrhythmia susceptibility through multi-target effects on ion channels and cardiac tissue.
WenXin keli is a traditional Chinese medicine formulation that modulates cardiac electrophysiology and reduces arrhythmia susceptibility through multi-target effects on ion channels and cardiac tissue. Used for Atrial fibrillation, Supraventricular arrhythmias.
At a glance
| Generic name | Low dose WenXin keli |
|---|---|
| Also known as | the original quantity Wenxin keli |
| Sponsor | Beijing Bozhiyin T&S Co., Ltd. |
| Drug class | Traditional Chinese medicine herbal formulation |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Low-dose WenXin keli contains a blend of herbal components traditionally used in Chinese medicine to treat cardiac arrhythmias. The formulation is believed to work by stabilizing cardiac action potentials, modulating potassium and calcium channel activity, and reducing abnormal automaticity in cardiac tissue. It has been studied primarily for its antiarrhythmic properties in atrial fibrillation and other supraventricular arrhythmias.
Approved indications
- Atrial fibrillation
- Supraventricular arrhythmias
Common side effects
- Gastrointestinal upset
- Dizziness
- Palpitations
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Low dose WenXin keli CI brief — competitive landscape report
- Low dose WenXin keli updates RSS · CI watch RSS
- Beijing Bozhiyin T&S Co., Ltd. portfolio CI